Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review

Abstract: Gliomas are the most common tumor of the central nervous system. However, the presence of the brain barrier blocks the effective delivery of drugs and leads to the treatment failure of various drugs. The development of a nanoparticle drug delivery system (NDDS) can solve this problem. In this review, we summarized the brain barrier (including blood–brain barrier (BBB), blood–brain tumor barriers (BBTB), brain–cerebrospinal fluid barrier (BCB), and nose-to-brain barrier), NDDS of glioma (such as passive targeting systems, active targeting systems, and environmental responsive targeting systems), and NDDS efficacy improvement strategies and deficiencies. The research prospect of drug-targeted delivery systems for glioma is also discussed.

Keywords: glioma, brain barrier, nanoparticle drug delivery system, efficacy improvement strategies, deficiencies of NDDS

Introduction

Cancer remains the most threatening disease to human life and health. The cancer mortality rate remains alarming despite recent advances. In 2016, there were 330,000 new cases and 227,000 deaths from central nervous system (CNS) tumors. Glioma is the most common CNS tumor (40–50%) with an annual incidence of 3–8 cases/100,000 people. The World Health Organization (WHO) classifies glioma into four grades: WHO grade I and II tumors are low-grade gliomas including astrocytomas, oligodendrogliomas, dysembryoplastic neuroepithelial tumor, gangliogliomas, and mixed glioma. WHO III and IV are high-grade gliomas (malignant gliomas, MG) including anaplastic astromassa, oligodendroglioma, ependymoma, glioblastoma, and gliosarcoma. MG is more aggressive and worse prognosis. The 5-year survival rate in grade IV patients was less than 5%. Three conventional methods are usually used in clinical treatment: surgical treatment, radiotherapy, and chemotherapy. However, it is difficult to carry out an accurate resection due to the infiltrative growth of glioma. Furthermore, radiotherapy and chemotherapy greatly and negatively impact the quality of life.

Nano-targeted agents are drug delivery systems that integrate drugs into different nanocarriers to concentrate them in targeted tissues/organs. This strategy is also called a nanoparticle drug delivery system (NDDS) and offers high drug stability, sustained release potential, and low drug toxicity to solve these issues. NDDS can increase the blood-drug concentration, prolong the half-life, and reduce the drug
delivery frequency by improving solubility, stability, and bioavailability of hydrophobic drugs. Thus, NDDS is an active area of research. However, the diagnosis and treatment of glioma remain difficult because the brain barrier restricts drug transport to the brain.

In this review, we summarize the biological characteristics of various brain barriers and other neural barriers that limit the delivery of brain-targeted drugs as well as the shortcomings of existing work. The latest progress in targeted drug delivery in glioma was discussed (Figure 1). The characteristics and advantages of NDDS are introduced, and strategies for enhancing brain targeting drug delivery are summarized. Finally, possible development directions are predicted.

**Research Difficulties or Challenges**

**Brain Barriers**
Brain barriers are structures that prevent certain harmful substances from entering the brain. They are composed of blood–brain barrier (BBB), blood–cerebrospinal fluid barrier, and brain–cerebrospinal fluid barrier (BCB). In addition, there are blood-brain tumor barriers (BBTB) in brain tumor tissues.

**BBB**
Ehrlich first identified BBB in 1885 when he discovered that intravenous dyes could stain most organs except the brain. The BBB excludes almost all macromolecular drugs and more than 98% of small molecules. The BBB is mainly composed of brain capillary endothelial cells (BCECs), which can differentiate into pericytes, astrocytes, and neurons. Most importantly, the BCECs prevent cross-cell transport of compounds from blood to brain, which greatly restricts the passive diffusion of compounds. Therefore, many studies have worked to develop targeted-NPs that can overcome BBB to improve the treatment and diagnosis of glioma—examples include liposomes, nanomicelles, microspheres, or nanoemulsions. The structure and drug transport route of the BBB is shown in Figure 2.

![Figure 1 Schematic diagram of this review.](image-url)
BBTB
The vascular permeability increased when the BBB was destroyed, but some nourishing blood vessels of the tumor retained the characteristics of the BBB, which forms the BBTB. Similar to the BBB, the BBTB is composed of specific endothelial cells located between tumor cells and tumor blood vessels. Some receptors are highly expressed in the blood vessels of brain tumors and thus facilitate ligand-dependent drug transport to provide convenience for targeting drugs in tumor tissues. The BBTB contains three distinct microvascular groups: continuous, nonporous capillaries (similar to normal blood vessels), continuous, porous capillaries, and capillaries with gaps between endothelial cells. Although the BBTB is more permeable than the BBB, its presence still prevents the use of drugs in cancer therapy. Therefore, finding a way to facilitate drugs to cross the BBTB is crucial for drug treatment of glioma.

BCB
In the ventricular system, a ventricular tube separates the cerebral spinal fluid and brain tissue. The BCB is composed of ependymal epithelial cells and astrocytes, and its high permeability makes it easy for substances in cerebrospinal fluid to enter brain tissue through ependymal. Therefore, drugs that do not easily cross the BBB can be injected directly into the cerebrospinal fluid in clinical practice so that it can enter the brain tissue quickly. After intrathecal injection, drugs can pass through the subarachnoid space and reach the cerebrospinal fluid to directly reach the brain tissue without passing the BBB. It has rapid effects and is suitable for the prevention and treatment of meningopathy or malignant tumor metastasis.

Nose to Brain Barrier
Nasal administration can also allow more drugs to reach the brain than peripheral intravenous administration. There are two parts of the nasal cavity (the breathing area and the olfactory area)—these are responsible for absorbing drugs into the brain or blood. Some drugs are absorbed into blood circulation through the mucous membrane of the respiratory department and then enter the brain tissue through the BBB. Other drugs bypass the BBB and enter the brain tissue directly through the olfactory mucous membrane or nerve. Of these pathways, the olfactory mucous pathway is the fastest and main route—the drugs travel from the nasal cavity to the brain. Indeed, humans only receive tiny amounts of drugs (25–200 µL) from the 3–10% mucous membrane, which limits the concentration of drugs delivered to the brain. Moreover, the clearance of nasal cilia can shorten the drug absorption time. Drug metabolism and secretion can also inhibit drug access to
the brain. Furthermore, long-term nasal administration can produce toxic and side effects on the nasal mucosa and cilia.\textsuperscript{32}

Security Issues
Anti-tumor drugs can have off-target effects including neurotoxicity to normal tissues due to low selectivity. Furthermore, drug resistance and dose toxicity after long-term chemotherapeutic drug use are also serious problems.\textsuperscript{10} Second, drug carriers generally have poor biodegradability and long-term safety concerns.\textsuperscript{33} Peptides and antibodies are exogenous substances used for targeting but are often not selective to the brain and are highly unstable and immunogenic. Third, carrier-mediated active targeting and endocytosis are highly dependent on the corresponding receptor expression density of glioma cells. Individual differences are common among patients. Thus, it is quite likely to activate the rejection mechanism of the immune system (reticuloendothelial system and mononuclear phagocytic system).\textsuperscript{16,22,34}

Molecular Weight of Drug Carriers
PEG or other polymers are commonly used as drug carriers in NDDS. However, the molecular weights (MW) of polymers range from a few thousand to tens of thousands. Polymers with appropriate MW can reduce the adsorption of serum protein and the recognition ability of the immune system. PEG\textsubscript{2000}, PEG\textsubscript{3000}, and PEG\textsubscript{3400} are often used, but there are few studies that carefully evaluate the most appropriate MW in glioma therapy. Different MW polymers should be used for NPs with different targeted functions. For the passive targeting drug delivery system (PTDDS) and the environmental responsive targeting drug delivery systems (ERTDDS), polymers with a large MW can lead to sufficient residence time to act on the EPR effect and promote NPs to enter the target site. For the active targeting drug delivery systems (ATDDS), polymers with a small MW can minimize interference between BBB-targeted ligands and BBB interactions—this is more conducive to vector-mediated endocytosis.\textsuperscript{35}

Properties of NPs
In addition, the size and morphology of NPs can greatly impact the efficiency of glioma treatment. The size only influences the tumor retention and penetration and also affects the BBB targeting and penetrating efficiency. Size changes are an enhancement strategy for glioma therapy and have been described in detail in “Reduction of the particle size of drug delivery system”. The shape of nanoparticles also affects endocytosis between BBB and cell membranes. Rod/chain-like targeted NPs have higher brain accumulation than spherical NPs.\textsuperscript{36} Other NP features include surface charge, ligand density, ratio of dual-targeting systems, and water solubility.

Application of NDDS
NDDS can be classified into passive targeting systems, active targeting systems, and environmental responsive targeting systems according to their different modes of action.\textsuperscript{37,38} Part of the glioma drug delivery system and the relative mechanisms are shown in Figure 3 and Table 1. Nano-carriers are mainly used in passive targeting systems to encapsulate drugs such as nanoparticles, liposomes, and microspheres.\textsuperscript{39} Drug-containing nano-carriers are naturally engulfed through the physiological process of cell endocytosis to achieve targeted drug distribution. Besides, various targeted molecules act as “missiles” to modify drug-carrying nano-carriers such as proteins, antibodies, small molecules, or nucleic acid aptamers. These are common in activetargeting systems and deliver drugs through a directional role to target sites.\textsuperscript{40} Moreover, the physicochemical targeting system could realize the targeted distribution of drug-carrying nanocarriers in the body through physical and chemical effects such as magnetism, heat, sound, light, electricity, and pH.\textsuperscript{41}

Passive Targeting Drug Delivery System
The PTDDS mainly delivers drugs to tumor tissues based on the “enhanced permeability and retention effect” (EPR effect) in tumor tissues instead of normal tissues.\textsuperscript{32} Interestingly, in the late stage of brain tumors, passive targeting nanoparticles can even enter the brain tumors through gaps in the endothelium due to the weak difference of EPR effect between tumor tissues and peripheral tissues. The most common passive-targeting drug delivery systems include liposomes, microemulsions, and nanoparticles.

Liposomes
Liposomes are spherical vesicles formed by phospholipid bilayer membranes that have attracted wide interest in biocompatibility and targeting with BBB. They are a common carrier for glioma PTDDS.

The elemene liposome (EL) injection was approved by the China Food and Drug Administration (CFDA) in 1994. More than 20 years of clinical studies have shown that EL is a non-cytotoxic anti-cancer drug with a high content of anti-cancer active ingredients (β-elemene, 85%).\textsuperscript{43,44} It can
suppress varieties of cancer cells and improve the immune system. It has obvious effects on improving patients’ quality of life, prolonging the survival period, resisting metastasis and recurrence, and reversing multiple-drug resistance (MDR), etc. EL has benefited more than 7.07 million cancer patients in southeast Asia, Hong Kong, Japan, Korea, Europe, and the US.\(^5\) Zhu et al\(^6\) found that EL (48 h) significantly accelerated the apoptosis initiation time of C6 glioma cells versus the normal elemene group (72 h). Moreover, Gao et al\(^7\) formulated the temozolomide-liposome (TL) that could be distributed in the brain. The \(t_{1/2}\), mean residence time (MRT), \(C_{\text{max}}\), and AUC values of TL were several-fold higher than the solution, which showed that TL could improve the therapeutic effect of the brain, reduce heart-lung toxicity, and prolong the circulation time of TZM in vivo.

**Microemulsions**

Microemulsions are drug delivery systems formed spontaneously in the water phase and oil phase with surfactant...
### Table 1 Application and Mechanism of Glioma Drug Delivery Systems

| NDDS       | Types                     | Mechanisms                                                                 | Ref.   |
|------------|---------------------------|-----------------------------------------------------------------------------|--------|
| **PTDDS**  |                           |                                                                             |        |
| Liposomes  | Phospholipid bilayer      | EPR effect/ across the endothelial cells of BBB                              | 46,47  |
| Microemulsions | P-gp/endocytosis       | EPR effect/ inhibition of P-gp efflux/ across the endothelial cells of BBB  | 49,51  |
| Niosome    | P-gp                      | EPR effect/ inhibition of P-gp efflux                                       | 87,88  |
| Nanoparticles | Endothelial cells        | EPR effect/ transcytosis or endocytosis                                    | 57,59  |
| **ATDDS**  |                           |                                                                             |        |
| Receptor-mediated | Insulin                  | Endocytosis/ insulin receptor                                               | 89     |
|             | Transferrin               | Endocytosis/ transferrin receptor                                           | 71     |
|             | Lactoferrin               | Endocytosis/ lactoferrin receptor                                           | 73,74  |
|             | Endothelial growth factors| Endocytosis/ endothelial growth factors receptor                           | 90     |
|             | Amino acids               | Endocytosis/ amino acids receptor                                           | 91     |
|             | Apolipoproteins/ angiopep-2| Endocytosis/ low density lipoprotein receptor                             | 92,93  |
|             | H-ferritin                | Endocytosis/ HFn receptor (transferrin receptor 1)                         | 72     |
| Peptide-mediated | iRGD                    | Endocytosis/ αvβ3/αvβ5                                                     | 78     |
|             | RDP                       | Endocytosis/ nerve-penetrating properties                                   | 82,83  |
|             | Chlorotoxin               | Endocytosis/ matrix metalloproteinase-2                                    | 54     |
|             | T7                        | Endocytosis/ transferrin receptor                                           | 94     |
|             | CDX peptide               | Nicotinic acetylcholine receptors                                           | 95     |
|             | F3                        | Bind to nucleolin                                                          | 96     |
|             | CendR motif               | Neuropilin-1/ across the endothelial cells                                 | 97     |
| Small molecule-mediated | Folic acid              | Folate receptor                                                             | 85     |
| Apt-mediated | AS1411/FB4                | Recognize proteins/ phospholipids/ nucleic acids                            | 98,99  |
| Cytokine-mediated | Interleukin-13       | IL-13Ra2 receptor                                                           | 100    |
| Matrix metalloproteinases-mediated | MMP-9            | Key modulators of tumor invasion/ metastasis                              | 101    |
| Cell-mediated | Mesenchymal stem cells    | Endocytosis/ across the endothelial cells of BBB                           | 102    |
|             | Macrophages               | Endocytosis/ across the endothelial cells of BBB                           | 103    |
| Dual targeting-mediated | Transferrin-folic acid  | Promote drug across BBB/ targeting tumor cells                             | 66     |
|             | Ang-2-VEGF receptors      | Endothelial growth factors receptor/ low density lipoprotein receptor      | 104    |
|             | T7.5°A7R-LS               | Transferrin receptor/ VEGF receptor 2                                      | 105    |
|             | Thermosensitive-PINS      | Winding-contraction phase transition / nerve-penetrating properties         | 106    |
|             | Transferrin-pH            | Promote drug across BBB/ pH difference                                      | 107    |
|             | pH-reduction              | pH difference and glutathione/dithiothreitol                              | 108    |

(Continued)
and cosurfactants. Oil phase components can increase the affinity of drugs to BBB endothelial cells, and surfactants/cosurfactants can inhibit or reduce P-gp efflux.\textsuperscript{45,48} Li et al\textsuperscript{49} constructed a microemulsion containing linoleic acid conjugated with paclitaxel (CLA-PTX) against brain tumors. The CLA-PTX microemulsion had a lower IC\textsubscript{50} and a higher tumor inhibition rate than CLA-PTX solution and free PTX, which is possibly because of the higher affinity of CLA-PTX to BBB endothelial cells and the enhanced permeability and retention effect for passive targeting. Xie et al\textsuperscript{50,51} prepared a hyaluronic acid chitosan-based microemulsion (HAC-ME), which significantly increased the BBB permeability of glioma cells after 0.25 h of administration. The material down-regulated the expression level of the tight junction protein claudin-5. Carboplatin combined with HAC-ME can promote the apoptosis of glioma cells versus free carboplatin.

### Nanoparticles

Nanoparticles are widely used in the treatment of glioma.\textsuperscript{52–54} An et al\textsuperscript{55} designed realgar nanoparticles (RN) that could significantly increase the proportion of C6 cells in S and G2/M phases. This decreased the proportion of C6 cells in the G0/G1 phase, downregulated Bcl-2 expression, and substantially upregulated Bax expression versus free realgar and control. Jain et al\textsuperscript{56} fabricated surface-modified PLA nanoparticles loaded with TMZ. Such PLA-NP nanoparticles can significantly increase the accumulation of the macromolecular dye coumarin-6 in the brain and reduce the accumulation in other organs. These results indicated that the nanoparticles could enhance the permeability of drug transport across the BBB into the brain. Thus, nanoparticles have potential value in glioma treatment and may reduce drug toxicity to other organs.

Many other nanomaterials have been used to treat glioma including chitosan that can effectively prolong the time of drug action and increase circulation.\textsuperscript{57} Dendritic polymers can improve drug release and biocompatibility.\textsuperscript{58} Macromolecular block copolymer micelles have a long cycle capacity and high stability.\textsuperscript{59}

### Active Targeting Drug Delivery Systems

However, the PTDDS has unfortunately not shown clinical value due to a lack of selectivity and affinity—this can lead to toxicity and side effects in normal tissues.\textsuperscript{34,40,60} Therefore, many researchers are working on ATDDS to achieve selective treatment of glioma.\textsuperscript{61} ATDDS are designed to exploit differences in receptors or antigen expression on the surface of tumor cells and normal cells. By virtue of the high affinity between ligand and receptors, ATDDS can achieve higher cross-BBB transport ability or tumor penetration. These features promote selective drug targeting with anti-tumor activity. Common active targeting vectors include small molecules, proteins, peptides, and aptamers; examples include folic acid, transferrin, and the RGD peptide.\textsuperscript{62–69}

### Receptors-Mediated ATDDS

Many receptors are expressed in the BBB including receptors of insulin, transferrin, endothelial growth factors, and amino acids. Receptor-mediated endocytosis is one of the main mechanisms by which drugs cross the BBB into the brain.\textsuperscript{70} Herein, researchers have modified nano-carriers with proteins to improve the ability of transporting across BBB and to improve the effectiveness of glioma drugs. Sun et al\textsuperscript{71} fabricated TMZ/transferrin (Tf)-nanoparticles (PAMAM-PEG-Tf/TMZ) that successfully crossed the BBB and killed glioma tumor cells. These particles lead to

| NDDS | Types | Mechanisms | Ref. |
|------|-------|------------|-----|
| Photo-sensitive | Photosensitizer/photothermal agent | ROS/singlet oxygen/local hyperthermia | 109–111 |
| pH-sensitive | Acidic microenvironment | pH difference | 112 |
| Reduction-sensitive | Disulfide bond | Glutathione/dithiothreitol | 113,114 |
| Magnetic sensitive | Magnetic resonance | The magnetic field | 115 |
| Ultrasonic sensitive | Ultrasonic | Ultrasonic cavitation effect | 116 |
| Thermo-sensitive | Hydrogen bonding | Winding-contraction phase transition | 106 |

Table 1 (Continued).
Fan et al. prepared a human H-ferritin (HFn) nanocarrier. The main entry point is HFn receptor 1, which is overexpressed in BCECs and glioma cells. In contrast, when specifically targeted and loaded into glioma cells, nearly all HFn accumulates in lysosomes leading to the death of glioma tumor cells— the surrounding healthy brain tissues do not have HFn aggregation. Such anti-glioma tumor activity is shown in Figure 4.

Similarly, Chen and Li et al. used a lactoferrin-modified PEG-poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles loaded with shikonin and procationic liposomes loaded with doxorubicin (DOX) for glioma therapy. The drug delivery system modified by lactoferrin can promote the drug-carrying nanoparticles across BBB so that the drugs can be enriched in the brain and achieve better efficacy.

**Peptides-Mediated ATDDS**

Polypeptides are small molecules composed of 2–50 amino acids with non-advanced structure. When ligand peptides bind to receptors, nano-carriers linked to peptides generally enter cells through receptor-mediated endocytosis. For example, RGD peptide including cyclic RGD peptide (cRGD) or internalizing RGD peptide (iRGD). Cell-penetrating peptides (CPPs) such as rabies-derived peptide (RDP) are also of interest because they can transport exogenous molecules to tumor tissues.

Gu et al. modified PEG-PLA nanoparticles containing PTX with MT1-AF7p peptide (MT1-NP-PTX). This material has obvious anti-proliferation activity on C6 glioma cells with IC\textsubscript{50} values of 2.81– and 2.47-fold lower than free PTX and NP-PTX, respectively. The percentage apoptosis of MT1-NP-PTX was the highest versus PTX and

---

**Figure 4** HFn-encapsulated Dox effectively improves anti-glioma tumor activity. (A) In vivo BLI images of GBM tumor cells in orthotopic mice that were intravenously injected with different formulations, ie, HFn-Dox, Doxil, free Dox, and HFn protein. (B) Quantitative analysis (n=5) of the BLI signals of (A). The red arrows indicate the time points of administration. (C) Animal survival curves in different groups. Asterisks indicate that the difference between HFn-Dox and free Dox or Doxil was statistically significant (Kaplan–Meier, p=0.0019 and 0.0023, respectively). (D) The effect of different treatments on mouse body weight (mean±SD, n=5). Reprinted with permission from Fan K, X Jia, M Zhou, et al. Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma. *ACS Nano*. 2018; 12(5): 4105–4115. Copyright (2018) American Chemical Society.
NP-PTX, which suggested more PTXs were delivered when combined with iRGD (high-affinity for cancer-related integrins such as αvβ3 and αvβ5). Zhao et al. established RDP-conjugated curcumin-coated nanoliposomes (RCL). Expectedly, the growth inhibition efficiency of RCL was 3.33-fold higher than curcumin liposomes (CL) in U251MG. The results of anti-glioma activity showed the survival time of glioma model mouse in the RCL group was longer than model and CL. In addition, RDP-p53 could efficiently and selectively enter and inhibit SH-SY5Y cells; the total percentage of apoptotic cells of RDP-p53 significantly improved versus the PBS and p53. All of the above showed that RDP-mediated nano-carriers were promising options for glioma therapy.

Small Molecule-Mediated ATDDS

Small molecules, such as folic acid (FA), biotin, and bisphosphonate, are often used as targeted ligands in ATDDS for tumors. They offer good safety, no immunogenicity, and easy modification. FA is the most widely used because the folate receptor (FR) is highly expressed on many cancers but not in normal tissues. Xu and Li et al. proposed a nano-targeted delivery of DOX for glioma based on PAMAM G5 dendrimer. The therapeutic effect of glioma was significantly improved after FA modification. The tumor growth inhibition of FA-PAMAM/DOX was increased up to 57.44%, while free DOX was 17.70% only. Meanwhile, FA-PAMAM/DOX could significantly reduce tumor volume in mice. Moreover, the data show that FA-PAMAM/DOX could significantly prolong the half-life time and improve DOX accumulation in brain tumor versus DOX. The MST of xenograft rats of FA-PAMAM/DOX was obviously longer than free DOX. This novel strategy of targeting nano-carriers modified with FA offers a promising way to increase the accumulation of drugs at tumor sites.

Aptamer-Mediated ATDDS

Aptamers (Apt) are oligonucleotides that can be synthesized chemically to promote targeted drug delivery. Compared with other targeted molecules, Apt attracted more and more attention due to their specific binding ability, high affinity, and low immunogenicity. Apt could easily penetrate tumor tissues because they can specifically identify target molecules such as proteins, phospholipids, sugars, and nucleic acids. Of these, AS1411 has extensive application value and potential development ability in clinical treatment of tumor—it could inhibit the growth of a variety of tumor cells without affecting normal cells. Luo et al. established a nanoparticle with AS1411-functionalized poly (l-γ-glutamyl-glutamine)-PTX (AS1411-PGG-PTX). The percentage of apoptosis of S1411-PGG-PTX was significantly increased versus PGG-PTX. In addition, the MST of mice in the AS1411-PGG-PTX group was significantly longer than the PTX group and the saline group. This might be due to the good stability in blood, long circulation time, and more accumulation of PTX in glioblastoma tissues. Mu et al. combined FB4—a segment of RNA that can specifically bind to transferrin receptor—with micelles loaded with flurbiprofen and conducted in vitro experiments with bEND5 cells (brain microvascular endothelial cells) in mice. Compared with untargeted micelles, the drug concentration in the micelles with FB4 ligand increased by 1.67-fold.

Cytokine-Mediated ATDDS

Human interleukin-13 (IL-13) is a cytokine secreted by activated T cells and has two receptors (IL-13/4R and IL-13Ra2). It can induce pro-inflammatory and anti-inflammatory immune responses. IL-13/4R is present in normal cells and binds to IL-4, whereas IL-13Ra2 is associated with glioblastoma but not expressed in normal tissues. A recent study showed that IL-13Ra2 receptor is overexpressed in the most common hair cell astrocytomas in children. Therefore, it is a promising target for cytotoxic drugs in various brain tumors.

For example, Madhankumar et al. prepared a DOX liposome modified with IL-13 to guide the liposome to the tumor site by binding to the over-expressed IL-13Ra2 receptor in glioblastoma. Compared with free DOX, liposomes modified with IL-13 enhanced cytotoxicity and increased the accumulation/retention of DOX in glioma cells. After 7 weeks of i.v. injection, the average tumor volume in IL-13-modified DOX liposome group had a 5-fold reduction compared with the non-targeted DOX liposome group. These data show that IL-13 targeted nanovesicles are a viable option for the treatment of brain tumors.

Stem Cell-Mediated ATDDS

Recent studies showed that the application of cell-modified nanoparticles for drug delivery system is an effective method to encourage the drugs to pass through for drug delivery. These drugs have an affinity for brain tumors and can be used as a drug carrier for the treatment of glioma such as mesenchymal stem cells (MSCs). Wang et al. manufactured MSCs loaded with PTX-encapsulated PLGA NPs to demonstrate the therapy for orthotopic glioma in rats. The PTX-migration rate of
MSC-loaded PTX-PLGA NPs increased by 44.4±5.4%, and MSC-loaded PTX-PLGA NPs had enhanced sustained PTX release to induce glioma cell death compared with PTX-PLGA NPs. Survival was significantly longer in control MSC-loaded PTX-PLGA NPs than those injected with PTX-PLGA NPs alone. These data suggest that MSC-loaded PTX-PLGA NPs are effective for glioma treatment and are a promising strategy for tumor-targeted therapy.

**Dual-Targeting-Mediated ATDDS**

Compared with PTDDS, ATDDS enhances the efficacy of glioma treatment via the two following aspects: (1) They promote drug delivery systems for transport across the BBB; (2) They selectively target glioma cells while increasing the distribution of drugs in glioma and reduce their distribution in normal brain tissues. Currently, most ATDDS have only one feature that allows drugs to be non-selectively distributed throughout the brain after passing through the BBB. This low selectivity can cause some serious neurological side effects. Thus, an ideal glioma TDDS should have the above two characteristics at the same time, i.e., dual-targeting-mediated ATDDS. Dual-targeting-mediated ATDDS usually refers to the modification of two functional ligands on the PTDDS. One is targeted to the BBB to promote the cross-BBB transport of the drug delivery system, and the other is targeted to the glioma tissue and further concentrates the drug in the glioma. A ligand, targeting both BBB and glioma, is connected to the PTDDS—this can also be called a dual-targeting-mediated ATDDS.²

Gao et al⁶⁶ prepared DOX liposomes modified by transferrin and folate (Tff-F-DOX-Lip). A near-infrared fluorescent probe showed that the fluorescence of DOX solution and DOX-Lip was mainly in the cardiac region, but Tff-F-DOX-Lip was mainly distributed in brain—these data illustrated that liposomes modified by transferrin and folate could promote the migration of liposome to the brain. The tumor inhibition rate of Tff-F-DOX-Lip was six-fold higher than DOX-Lip after i.v. administration. The data show that Tff-F-DOX-Lip could not only promote DOX for transport across the BBB but also increase the distribution of DOX in glioma.

**Environmental Responsive Targeting Drug Delivery Systems**

Traditional drug delivery systems are not ideal for maintaining system stability and promoting drug release at target sites. Therefore, the design of ERTDDS has gradually become a research hotspot in the field of pharmacy. To understand the physiological differences between tumors and normal tissues, ERTDDS can specifically respond to endogenous or exogenous stimuli including physical (such as photosensitivity¹⁰⁹,¹³²,¹³³), chemical (as pH sensitivity¹³⁴–¹³⁷ and reduction sensitivity¹¹³,¹³⁸), and biological (as matrix metalloproteinases¹³⁹) features. ERTDDS only responds to internal and external environmental conditions when it is close to the drug action site—these conditions then trigger the release of drugs in tumor tissues while remaining stable in other tissues. Thus, it can improve the anti-tumor efficacy and reduce the toxicity and side effects.

**Photo-Sensitive TDDS**

Photosensitive TDDS is a tumor therapy method based on photodynamic therapy (PDT) and photothermal therapy (PTT).¹⁰⁹,¹⁴⁰–¹⁴² It is based on light conditions reaching the photosensitive TDDS in the tumor site. Photosensitizer (PS) or photothermal agent (PA) will absorb the light, and reactive oxygen species (ROS), singlet oxygen, or local hyperthermia will be released. While preserving normal tissues, the nanoparticles selectively and efficiently produce cytotoxic activity and kill tumor cells.

Xu et al¹⁰⁹ constructed a therapeutic nano-platform (ICG-SFNPs) with silk fibroin (SF) to use indocyanine green (ICG) for PTT of glioblastoma. Meanwhile, the photothermal effect of ICG-SFNPS is more stable than free ICG under near-infrared radiation (NIR). After local NIR, the temperature of ICG-SFNPS rapidly increased by 33.9°C within 10 min and remained high for a long time to kill tumor cells. The growth of glioblastoma cells was completely inhibited by ICG-SFNPs.

Jia et al¹⁴² developed a biomimetic proteolipid nanoparticles (NPs) with ICG for phototherapy of orthotopic glioma in mice. Biomimetic ICG-loaded liposome (BLIPO-ICG) NPs were obtained by embedding the glioma cell membrane protein into NPs. Due to the good homologous targeting and immune escape characteristics, BLIPO-ICG NPs can pass through BBB and specifically bind to glioma cells and reach glioma in early stages. At 12 h post-injection, the signal-to-background ratio in the brain tumor reached 8.4 demonstrating good accumulation. In addition, after NIR (1 W/cm², 5 min), the photothermal effect of BLIPO-ICG NPs effectively inhibited the proliferation of glioma cells with an inhibition rate of 94.2%. No photothermal damage of normal brain tissue or other side effects of treatment were observed. These results indicate that the bionic protein lipid NP is a promising
phototheranostic nanoplatfrom for brain tumor-specific treatment. The mechanism and anti-glioma tumor activity are shown in Figure 5.

pH-Sensitive TDDS
The normal pH of human blood and interstitial fluid is usually alkaline (pH 7.4), while the tumor microenvironment is acidic (approximately 5.6). The slightly acidic environment is mainly caused by the rapid proliferation of tumor cells and excessive accumulation of lactic acid. In addition, most tumor cells are characterized by insufficient blood supply and slow excretion, which further acidify the tumor microenvironment. Using pH differences between tumor tissues and normal tissues, numerous researchers have constructed drug delivery systems via pH-responsive materials. These delivery systems can change their physicochemical properties such as swelling and increasing solubility during the transition from weakly alkaline to slightly acidic environment. Thus, it can further trigger the release of drug molecules in the package and play a targeted role in tumor therapy.

Yin et al developed a pH-sensitive prodrug (Lf-HA-DOX) by combining hyaluronic acid (HA) with DOX. The release of DOX in Lf-HA-DOX was 45%, 35%, and 12% at pH 5.0, 6.0, and 7.4 at 24 h, respectively. Furthermore, the geometric mean fluorescence intensity (GMFI) of DOX in the free DOX group was almost unchanged when the concentration of DOX changed; it increased in the Lf-HA-DOX group. Similarly, Li et al synthesized a pH-sensitive dual-targeting drug carrier (G4-DOX-PEG-Tf-TAM) with conjugated Tf and Tamoxifen (TAM) of the PAMAM dendrimers for enhancing the BBB transportation and improving the drug accumulation in the glioma cells. They found that the DOX release was 32% at pH 4.5 and 6% at pH 7.4 indicating that the drug release is relatively fast at weak acidic conditions and stable in normal physiological environments.

Reduction-Sensitive TDDS
Reduction-sensitive TDDS refers to the particle delivery system connected by a disulfide bond (S-S) between the carrier and the drug. These particles self-assemble in solvent to form a nanostructure. Disulfide bonds are a special yet common chemical bond that is stable in normal physiology. However, they are broken in tumor tissues (reductive environment) with high expression of dithiothreitol and glutathione (GSH) to release the drug and achieve targeted release. Indeed, reduction-sensitive TDDS are reduction-sensitive and biodegradable and are an ideal platform for targeted tumor chemotherapy.

Zhu et al showed a biodegradable PEG-SS-PCL micelle functionalized by cRGD (cRGD/PEG-SS-PCL).
These materials can enhance DOX delivery in a reductive environment (10 mM GSH) to significantly improve tumor inhibition and decrease toxicity upon comparison with nontargeting agents and reduction-sensitive cRGD/PEG-PCL. Su et al\textsuperscript{150} proposed a novel copolymer mPEG-PAsp (MEA)–CA. The DOX was only slightly released in the absence of GSH. However, there was 37% DOX released after only 2 h when 10 mM GSH was added indicating that GSH broke the S–S through a thiol-disulfide exchange reaction to promote the release of DOX.

ERTDDS are also thermosensitive,\textsuperscript{106} magnetic sensitive,\textsuperscript{115,154} and ultrasonic sensitive,\textsuperscript{155} They are a research focus in recent years and can also specifically target the treatment of glioma under different conditions without affecting normal tissues.

**Strategies to Improve the Drug Targeting to Glioma**

**Reduce the Particle Size of the Drug Delivery System**

A smaller (200–800 nm) particle can usually be easily endocytosed by phagocytes. However, when the particle size is less than 200 nm, the curvature of local areas on the surface of the carrier will also decrease as the particle size decreases. Therefore, the particles could avoid being adsorbed by receptors on the surface of the phagocytes—they can escape phagocytosis and be cleared by phagocytes.\textsuperscript{156,157}

Wan et al\textsuperscript{158} placed tartaric acid vinorelbine liposomes with particle size of 200 nm and 800 nm in medium containing mouse mononuclear macrophage RAW264.7 and luciferin, respectively. After 12 h, the probability of devouring liposomes with particle size of 200 nm was 13%, while that of 800 nm was only 8%. Bi et al\textsuperscript{159} injected curcumin nano-suspension with the size of 70 nm (A) and 200 nm (B) into the body. The AUC\textsubscript{0–60min} of A was 2.58 times higher than B in the brain. When the size of the curcumin decreased from 200 nm to 70 nm, the AUC\textsubscript{0–60min} of liver drug also decreased from 8491 ng·min·g\textsuperscript{-1} to 2300 ng·min·g\textsuperscript{-1}. These results indicate that the size decrease can not only promote drug delivery to the brain but also reduce drug uptake by the liver. This is critical for the treatment of brain diseases and the reduction of drug toxicity and liver side effects.

**Structural Modification**

Studies have shown that small lipophilic drug molecules with a molecular weight of less than 500 Da can cross the BBB by passive diffusion. Therefore, small-molecule drugs can have improved properties by modifying their polar groups such as esterification and alkylation of hydroxyl or carboxyl groups. Non-polar groups such as methyl and benzene rings can also be introduced to increase lipophilicity and improve BBB transmittance.\textsuperscript{160,161}

Chen et al\textsuperscript{162} designed and synthesized a series of novel derivatives to improve the anticancer efficacy of natural β-elemene. Most derivatives exhibited significant anti-proliferative activities against the three cancer cell lines (SGC-7901, HeLa, and U87) versus natural β-elemene. Interestingly, these compounds displayed excellent sensitivity to glioma cells. Moreover, further mechanistic studies revealed that 11a caused the G2 phase arrest of the cell cycle and induced apoptosis of glioma cells by preventing the activation of the PI3K/Akt pathway. In addition, 11a significantly suppressed the tumor growth in cancer xenograft mouse model, which was superior to β-elemene at the same condition. In conclusion, the remarkable biological properties of these new β-elemene derivatives may make them promising candidates for glioma treatment.

**Combination with Resuscitative CHMs**

Resuscitative CHMs\textsuperscript{163,164} are traditional Chinese medicines considered “orifice-opening” agents including musk, borneol, acorus gramineus, and benzoin. With spicy and fragrant attributes, Resuscitative CHMs can better enter the brain tissue through the BBB. The active ingredients have strong lipid solubility and minimal molecular weights. In addition, resuscitative CHMs can also induce other drugs upward into the brain, ie, they can increase the permeability of BBB, promote drugs to pass through the BBB, and improve the efficacy of drugs. The cell structure is basically complete after this action. Pharmacological studies have found that resuscitative CHMs can increase the content of Evans blue (EB) in the brain tissue of normal mice confirming that Resuscitative CHMs can open the BBB in normal mice.

**Borneol**

The mechanism of borneol passing through BBB may be inhibition of transporters to increase the vasodilatory neurotransmitters and inhibit active transport of ion channels.\textsuperscript{165,166} P-glycoprotein (P-gp) is an effenter protein on the BBB. It can easily bind with a variety of substrates and expel them from brain tissues to reduce the therapeutic drug effects. Borneol inhibited the expression of P-gp to allow drugs to enter brain tissue. For instance, tanshinol has been
used to treat epilepsy and other brain diseases, but it will be excreted by P-gp within a short time after entering the brain. When borneol was introduced into tanshinol to form an esterification complex, it could easily travel through the BBB into the brain for a longer retention time. Moreover, the inhibitory effect on P-gp of borneol made the higher concentration of tanshinol play a role in brain tissue. The effect of borneol on aprotinase-modified nanoparticles can significantly increase the absorption of nanoparticles by capillary endothelial cells in the brain of Alzheimer’s disease and can improve memory. These data provide a new idea for targeted glioma drug delivery.

α-Asarone

Wu et al evaluated the “orifice-opening” effect of α-asarone (a main active ingredient of acorus gramineus) on the improvement of brain delivery of Puerarin (PUE) and tetramethylpyrazine (TMP). They then investigated whether the enhancing effects were associated with adenosine receptors (ARs)-mediated trans-BBB pathway. Their results indicated that α-asarone significantly increased the accumulation of permeated PUE and TMP, and the enhancing effects could be counteracted by AR inhibitors. Indeed, α-asarone decreased the expression of ZO-1 (an important BBB junction protein) and increased the expression of A1AR and A2AAR. Pharmacokinetic studies showed that oral administration of α-asarone significantly increased $AUC_{\text{brain}}$ 1.34-fold and 1.79-fold for PUE and TMP. These results suggested that α-asarone is an effective adjuvant agent for the delivery of PUE and TMP to the brain.

Application of Physical Technology

During ultrasonic processing, liquids undergo a series of dynamic processes such as vibration, growth, and rupture under the action of sound waves. When physical effects are applied to the cell interface of the surrounding tissues, tight junctions between cells become loose and reversible pores appear. This improves cell endocytosis. In addition, ultrasonic vibration can improve the permeability of cell membrane and promote drug uptake.

EB can bind with plasma albumin to form an EB-albumin complex, which has a large molecular weight and cannot penetrate the complete BBB. The gap between BBB cells becomes larger under the action of ultrasound, which may promote the passage of the complex through the BBB. Based on this hypothesis, Chen et al performed ultrasound treatment on the brains of rats successfully transplanted with tumor cells. The results showed that the compound could pass through BBB after i.v. injection. After injection of lipid microbubble solution and saline, the brain tumor sites of the two groups of rats were first treated with ultrasound (1.0 MHz). The EB solution was injected immediately, and glioma tumor tissues were extracted after 72 h. Under confocal laser microscope, only sparse red spots of fluorescence were observed in the control group, while many areas of red fluorescence were observed in the experimental group. This confirms that ultrasound can promote EB through BBB into glioma tissue.

Currently, ultrasound-mediated targeted therapy is still in the experimental stage. The appropriate ultrasound parameters for optimal drug delivery must be identified with studies for potential adverse reactions including bleeding, brain injury, and inflammation after the destruction of ultrasound BBB. Nevertheless, this technology is expected to lead to breakthroughs in targeted drug delivery to the brain and cancer therapy after the development of new ultrasound targeted therapy and continuous optimization of ultrasound parameters.

Alternative Routes of Administration

Nasal Drug Delivery

After nasal administration (NA), some drugs bypass the BBB and enter brain tissue directly through the olfactory mucosa or olfactory nerves. Compared with peripheral vein administration, NA allows increased delivery and faster transfer of drugs into the brain. Zhang et al administrated a β-asarone microemulsion through the nose and tail vein injection on rats. The results showed that β-asarum microemulsion was absorbed into the blood and brain tissues quickly and could be detected at 2 min after NA. However, the ratio of $AUC_{\text{brain}(0-2, min)}/AUC_{\text{plasma}(0-2, min)}$ was 1.49, and more drugs entered the brain with a nearly 50% higher amount of drug in brain tissues than in plasma. Meanwhile, a lower amount of drug could enter into the brain after caudal vein administration. Compared with NA, the concentration of β-asarum in the brain after i.v. administration was only 56.85% of the NA. This suggests that NA has unique advantages in promoting drug delivery to the brain and may be one of the pre-selected methods for glioma treatment.

Intrathecal Injection

Intrathecal injection (i.t.) refers to the injection of drugs into the spinal canal. The delivery of the cerebrospinal fluid plays a key role after delivery through the subarachnoid space. This approach is suitable for the prevention and/or treatment of meningial lesions, malignant tumor metastasis, and other diseases. The i.t. offers low dosages and targeted drug delivery.
delivery. It can be administered by a single puncture or multiple rounds of delivery after the sheath is implanted. After i.t., the drug can directly reach the target site through BCB without crossing the BBB for quick action.

Etminan et al used nimodipine microspheres for intrathecal injection, and the results showed that nimodipine microspheres could prolong drug release time, enhance healing effect, and reduce drug toxicity. While drugs act more directly when given i.t., they can cause more damage. Strategies for enhancing glioma treatment are shown in Table 2.

**Perspectives**

Due to the protective effect of the brain barrier on the brain, the clinical treatment of glioma still remains difficult. Brain-targeted drug delivery has attracted wide attention because of its slow release and controllable and targeted safety. Regardless of the target, drug targeting is based on the interaction between the dosage form characteristics of the drug delivery system and the specific physiological/pathological structure of the body. The development of biomimetic drugs/materials with homologous binding and immune escape functions has been regarded as the most ideal alternative. These drugs/materials use autologous tissues/cells/proteins from the human body as carriers to quickly reach the target site after entering the human body.

For example, NPs wrapped in glioma cell membrane or glioma cell membrane proteins were loaded on NPs. Under certain conditions, tumor cells are killed by various mechanisms such as starvation therapy and photodynamic/photothermal therapy. Strategies for enhancing glioma treatment are shown in Table 2.

### Table 2 Strategies for Enhancing the Treatment of Glioma

| Types                      | Strategies                        | Mechanisms                        | Enhancements                                      | Ref.  |
|----------------------------|-----------------------------------|-----------------------------------|---------------------------------------------------|-------|
| Use new drug delivery system | Free realgar realgar nanoparticles | EPR effect/endocytosis            | C6 cells apoptosis rate was increased by 5.30 times | 55    |
|                            | Free TMZ PAMAM-PEG -Tf/TMZ         | Endocytosis/Tf receptor            | MST of mice bearing gliomas was extended by 22.9 days |
|                            | Free TMZ TMZ-Lf/NPs                | Endocytosis/Lf receptor            | The concentration of TMZ in brain was higher 3 times; IST increased 1.4 times | 178   |
|                            | Free DOX Li-HA-DOX                 | Endocytosis/pH difference/Lf receptor | The GMFI of DOX was increased 8.71 times | 112   |
| Reduce the particle size    | 200nm 70nm                        | Promote drug delivery to the brain; reduce drug uptake by the liver; avoid being adsorbed by receptors on the surface of phagocytes, escaping phagocytosis and clearance by phagocytes | After 5 minutes of administration, the concentration in the brain improved 2-fold; after 20 min of administration, the concentration in the brain improved 3-fold; AUC0–60 min in the brain was 2.58 times | 169   |
| Structural modification     | β-elemene Derivatives-11a          | Caused the G2 phase arrest of the cell cycle; induced apoptosis of glioma cells by preventing the activation of the PI3K/Akt pathway | Tumor inhibitory ratio increased from 49.6% to 64.8% | 162   |
| Combination with resuscitative CHMs | Tanshinol Tanshinol-borneol esterification complex | Inhibit the expression of Pgp; reduce Pgp efflux | It was easy to travel through BBB to the brain with the higher concentration of tanshinol; had a longer retention time | 167   |
|                            | PUE and TMP Combination with α-asarone | Decrease expression of ZO-1, while increase the expression of A1AR and A2AAR | The accumulation of permeated PUE and TMP was increased; AUCbrain for PUE and TMP was increased 1.34-fold and 1.79-fold | 170   |
| Application of physical technology | EB-albumin complex Performed ultrasound treatment | The tight junctions between cells become loose and reversible pores appear; improved endocytosis of cells | Fluorescence intensity increased significantly | 173   |
| Change route of administration | Oral/ intravenous Nasal drug delivery/ intrathecal injection | Directly through the BCB without crossing BBB | i.v. administration was only 56.85% of the nasal administration/ prolong drug release time; enhanced healing and reduced drug toxicity | 30,176 |
photothermal therapy. In addition, as endogenous substances, it is difficult for the immune system to recognize the drug-carrying system in membrane disguise. Thus, these systems can escape rejection by the immune system for long therapy cycles. The carriers are gradually degraded or absorbed without accumulation in the body. Such bionic materials can be applied independently without chemotherapy drugs. Thus, they do not cause serious adverse reactions and might be safer.

Accordingly, the following four suggestions are proposed for further research on targeted agents for glioma. (1) While studying the brain-targeted delivery of drugs, researchers should also pay attention to the latest progress in basic research including structural characteristics, composition, and permeability of BBB and glioma. It is important to improve the efficiency of brain-targeted delivery of drugs. (2) Researchers should identify and evaluate the factors that affect the behavior of the glioma NDDS in vivo, which is the basis of the effectiveness. (3) Considering the perspective of biosafety, biodegradable material without immunogenicity or biotoxicity that can be removed from the brain should be utilized in glioma NDDS. (4) A unified preparation method should be developed to make NPs more uniform, stable, and controllable—this will ensure clinical efficacy.

Acknowledgments
This work was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No.LY18H180009), National Natural Science Foundation of China (Grant No. 61801160, 81730108), Key Project of Zhejiang Project Ministry of Science and Technology (2015C03055), and Key Project of Hangzhou Ministry of Science and Technology (20162013A07). We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.29210
2. Patel AP, Fisher JL, Nichols E, et al. Global, regional, and national burden of brain and other CNScancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):376–393. doi:10.1016/S1474-4422(18)30468-X
3. Norden AD, Drappatz J, Wen PY. Malignant Gliomas in Adults. Blue Books Neurol. 2010;36(10):99–120.
4. Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–1227. doi:10.1001/jamaoncol.2018.2128
5. Claus EB, Walsh KM, Wienieke JK, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015;38(1):E6. doi:10.3171/2014.10.FOCUS12367
6. Taiibi SS, Taiibi SS, Aweid B, et al. Prospective therapies for high-grade glial tumours: a literature review. Ann Med Surg. 2014;3(3):55–59. doi:10.1016/j.amsu.2014.04.003
7. Krivosheya D, Prabhu SS, Weinberg JS, et al. Technical principles in glioma surgery and preoperative considerations. J Neurooncol. 2016;130(2):243–252.
8. Flouty O, Reddy C, Holland M, et al. Precision surgery of rolandic glioma and insights from extended functional mapping. Clin Neurol Neurosurg. 2017;163:60–66. doi:10.1016/j.clineuro.2017.10.008
9. Hanna A, Birla R, Iosif C, et al. Benefits and Disadvantages of Neoadjuvant Radiochemotherapy (RCT) in the Multimodal Therapy of Squamous Esophageal Cancer (ESC). Chirurgia. 2016;111(1):12–25.
10. Park SB, David G, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. Ca a Cancer J Clin. 2013;63(6):419–437. doi:10.3322/caac.21204
11. Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updat. 2017;31:15–30. doi:10.1016/j.drup.2017.05.002
12. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.037
13. Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2015;24(3):179. doi:10.3109/1061186X.2015.1051049
14. Ashfaq UA, Riaz M, Yasmeen E, et al. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment. Crit Rev Ther Drug Carrier Syst. 2017;34(4):36. doi:10.1615/CritRevTherDrugCarrierSyst.201701845
15. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in Neuro-Oncology. 2006–2010;15 (suppl2):ii1–ii56.
16. Partridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13(7):963–975. doi:10.1517/17425247.2016.1171315
17. van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015;38(1):E6. doi:10.3171/2014.10.FOCUS12367
18. Obermeier B, Verma A, Ransohoff RM. The blood-brain barrier. Handb Clin Neurol. 2016;133(8246):39–59.
19. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discovery. 2016;15(4):275–292. doi:10.1038/nrd.2015.21
20. Chaves C, Remião F, Cisterninoa S, et al. Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. Curr Neuropharmacol. 2017;15(8):1156. doi:10.2174/1570159X15666170504095823
21. Matsumoto J, Stewart T, Banks WA, et al. The transport mechanism of extracellular vesicles at the blood-brain barrier. Curr Pharm Des. 2017;23(40):6206–6214. doi:10.2174/138161282366170913164738
22. Bhownik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. 2015;2015:1–20. doi:10.1155/2015/320941

23. Posadas I, Monteagudo S, Ceña V. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. Nanomedicine. 2016;11(7):833–849. doi:10.2217/nnm.15.16

24. Berghoff AS, Preusser M. Role of the blood-brain barrier in metastatic disease of the central nervous system. Handb Clin Neurol. 2018;149:57–66.

25. Emily K. Development of a Three-Dimensional, All-Human in vitro Model of the Blood-Brain Barrier for Cancer Metastasis Studies. University of Portsmouth; 2010.

26. Yin L, Li H, Liu W, et al. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in glioblastoma tissue. Eur J Med Chem. 2017;144:1–28. doi:10.1016/j.ejmech.2017.12.003

27. Weidle UH, Niewöhner J, Tiefenthaler G. The blood-brain barrier challenge for the treatment of brain cancer, secondary brain metastases, and neurological diseases. Cancer Genomics Proteomics. 2015;12(4):167.

28. Garcia MA, Carrasco M, Godoy A, et al. Elevated expression of glucose transporter-1 in hypothalamic ependymal cells not involved in the formation of the brain-cerebrospinal fluid barrier. J Cell Biochem. 2015;130(4):491–503. doi:10.1002/jcb.25244

29. Zhou J, Kong H, Hua X, et al. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport. 2008;19(1):1–5. doi:10.1097/WNR.0b013e3282284eb

30. Emtman N, Macdonald RL, Davis C, et al. Intrathecal application of the nimodipine slow-release microparticle system EG-1962 for prevention of delayed cerebral ischemia and improvement of outcome after aneurysmal subarachnoid hemorrhage. Acta Neurochirurgica Suppl. 2015;120:281–286. doi:10.1007/978-3-319-04981-6_47

31. Hongbing W, Kaili H, Xinguo J. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv. 2008;5(10):1159–1168. doi:10.1517/17425247.5.10.1159

32. Huang Meng-yao YX, Jin-feng XING, Zhen-ping WEI. Strategies for enhancing nanoscale brain targeting drug delivery. Acta Pharmac Sin. 2019;4:629–637.

33. Prieto A. To be, or not to be biodegradable . . . that is the question for the bio-based plastics. Microb Biotechnol. 2016;9(5):652–657. doi:10.1111/1751-7915.12393

34. Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34(1):424–436. doi:10.1515/dmpt-2018-0032

35. Gao H. Perspectives on dual targeting delivery systems for brain tumors. J Neuroimmun Pharmacol. 2016;12(1):6–16. doi:10.1007/s11481-016-9687-4

36. Richards DM, Endres RG. Target shape dependence in a simple model of receptor-mediated endocytosis and phagocytosis. Proc Natl Acad Sci U S A. 2016;113(22):6113. doi:10.1073/pnas.1521974113

37. Unsoy G, Gunduz U. Smart drug delivery systems in cancer therapy. Curr Drug Targets. 2018;19(3):202–212.

38. Jain KK. Current status and future prospects of drug delivery systems. Methods Mol Biol. 2014;114(5):1.

39. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 2010;197(197):3.

40. Yu S, Kuzuki K, Hiroto H, et al. Advances in an active and passive targeting to tumor and adipose tissues. Expert Opin Drug Deliv. 2015;12(1):41–52. doi:10.1517/17425247.2015.955847

41. Müller J, Martins A, Csábi J, et al. BBB penetration-targeting physicochemical lead selection: edestorydins as chemo-sensitizers against CNS tumors. Eur J Pharm Sci. 2017;96:571–577. doi:10.1016/j.ejps.2016.10.034

42. Maeda H, Sawa TMY, Hori K, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release. 2000;65(1):271–284. doi:10.1016/S0168-3659(99)00248-5

43. T CL X, Wang SL, Zeng ZW, Wang F, Zhao R. Advances in the research of Elemene Liposome series targeted anticancer natural drugs. Chin J Integr Tradit West Med. 2014;34(4):507–512.

44. Chen MW, Zhong ZF, Wang SP, WANG YT. Research progress in anticancer activity and novel delivery system of β-elemene. Chin J New Drugs. 2012;21(12):1358–1361.

45. Zhai B, Zeng Y, Zeng Z, et al. Drug delivery systems for elemene, its main active ingredinent β-elemene, and its derivatives in cancer therapy. [Cited]International Journal of Nanomedicine]. 2018;13:6279–6296. doi:10.2147/IJN.S174527

46. Zha YJ, Yue HU, Dong-Hang Xu. Effect of nano-liposome sustained element in inducing cell apoptosis of C6 glioma. Chin J Integr Tradit West Med. 2008;28(7):637–639.

47. Gao J, Wang Z, Liu H, et al. Liposome encapsulated of temozolomide for the treatment of glioma tumor: preparation, characterization and evaluation. Drug Discov Ther. 2015;9(3):205–212. doi:10.5582/drt.2015.01016

48. Xavier-Junior FH, Vauthier C, Morais AR, et al. Microemulsion systems containing bioactive natural oils: an overview on the state of the art. Drug Dev Commun. 2017;43(5):700–714.

49. Li D, Yang K, Li JS, et al. Antitumor efficiency of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings. Int J Nanomedicine. 2012;7:6105–6114. doi:10.2147/IJN.S38927

50. Xie H, Wei-Cheng LU, Ding XH, et al. Study of hyaluronic acid chitosan based microemulsion on the permeability of blood tumor barrier in rat. J China Med Univ;2014.

51. Lu W, Xie H, Ding X, Qi R, Xing H, Wu H. Therapeutic effect of hyaluronic acid chitosan-based microemulsion and carboplatin on glioma in rats. J Shenyang Med Coll. 2016;18(3):149–150.

52. Maryam R, Brian H, Nathan K, et al. The future of glioma treatment: stem cells, nanotechnology and personalized medicine. Future Oncol. 2012;8(9):1149–1156. doi:10.2217/ fon.12.111

53. Minghui L, Hongbing D, Haisheng P, et al. Functional nanoparticles in targeting glioma diagnosis and therapies. J Nanosci Nanotechnol. 2014;14(1):415–432. doi:10.1166/jnn.2014.8757

54. Zhao L, Shi X, Zhao J. Chlorotoxin-conjugated nanoparticles for targeted imaging and therapy of glioma. Curr Top Med Chem. 2015;15(13):1196–1208. doi:10.2174/1568026615666150330110822

55. An YL, Nie F, Wang ZY, et al. Preparation and characterization of realgar nanoparticles and their inhibitory effect on rat glioma cells. Int J Nanomedicine. 2011;6:3187–3194. doi:10.2147/ IJN.S26373

56. Jain D, Bajaj A, Athawale R, et al. Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies. Drug Deliv. 2014;39(1):1–18.

57. Wang J, Wang X, Cao Y, et al. Therapeutic potential of hyaluronic acid/chitosan nanoparticles for the delivery of curcuminoid in knee osteoarthritis and an in vitro evaluation in chondrocytes. Int J Mol Med. 2018;42(5):1–11.

58. Li M, Wang B, Wu Z, et al. Treatment of Dutch rat models of glioma using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells. Tumor Biol. 2015;36(10):7961–7966.

59. Gao X, Yu T, Xu G, et al. Enhancing the anti-glioma therapy of doxorubicin by honokiol with biodegradable self-assembling micelles through multiple evaluations. Sci Rep. 2017;7:43501. doi:10.1038/srep43501
60. Mukherjee A, Kumar B, Hatano K, et al. Development and application of a novel model system to study ‘active’ and ‘passive’ tumor targeting. Mol Cancer Ther. 2016;15(10):2541. doi:10.1158/1535-7163.MCT-16-0051

61. Yinan Z, Fenghua M, Chao D, et al. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15(6):1955–1969. doi:10.1021/bm5003009

62. Aigner A, Kägel D. Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs? Nanomedicine. 2018;13(1):89–103. doi:10.2217/nmm-2017-0230

63. Liu C, Yao S, Li X, et al. iRGD-mediated core-shell nanoparticles loading Carmustine and O6-berylguanine for glioma therapy. J Drug Target. 2016;24(3):235–246. doi:10.1080/106118616X.2016.1238901

64. Chi Y, Zhu S, Wang C, et al. Glioma homing peptide-modified PEG-PCL nanoparticles for enhanced anti-glioma therapy. J Drug Target. 2015;24(3):224.

65. Feng X, Yao J, Gao X, et al. Multi-targeting peptide-functionalized nanoparticles recognized vasogenic leptomeningeal mimicry, tumor neovascularization and glioma cells for enhanced anti-glioma therapy. ACS Appl Mater Interfaces. 2015;7(50):acsami.5b09934. doi:10.1021/acsami.5b09934

66. Gao JQ, Lv Q, Li LM, et al. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubicin liposomes. Biomaterials. 2013;34(22):5628–5639. doi:10.1016/j.biomaterials.2013.03.097

67. Madhankumar AB, Mrowczynski O, Patel S, et al. Interleukin-13 conjugated quantum dots for identification of glioma initiating cells and their extracellular vesicles. Acta Biomater. 2017;58:205–213. doi:10.1016/j.actbio.2017.06.002

68. Gao H, Zhang S, Cao S, et al. Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm. 2014;11(8):2755–2763. doi:10.1021/mp500113p

69. Zhu X, Zhou H, Liu Y, et al. Tranferrinct/aptamer conjugated mesoporous rutheinum nanosystem for reduced-controlled and targeted chemo-photodynamic therapy of glioma. Acta Biomater. 2018;82:143–157. doi:10.1016/j.actbio.2018.10.012

70. Smith MW, Mark G. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J Drug Target. 2006;14(4):191–214. doi:10.1080/10717544.2006.1050868

71. Sun T, Wu H, Li Y, et al. Targeting transferrin receptor delivery of doxorubicin-polymer conjugates. Adv Drug Deliv Rev. 2017;100:110–1113. doi:10.1016/j.addr.2016.03.008

72. Zhao M, Zhao M, Fu C, et al. Targeted therapy of intracranial glioma model mice with curcumin nanoliposomes. Int J Nanomedicine. 2018;13:1601–1610. doi:10.2147/IJN.S157019

73. Wu J, Zhang E, Fu A, et al. A novel cell-permeable RDP-p53 fusion protein for specific inhibition on the growth of cancerous neural cells. Drug Deliv. 2015;23(7):1. doi:10.3109/10717544.2015.1013199

74. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284–293. doi:10.1016/j.ab.2004.12.026

75. Xu XL, Li JJ, Han SP, et al. A novel doxorubicin loaded folic acid conjugated PAMAM modified with bongeol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration. Eur J Pharm Sci. 2016;88:178–190. doi:10.1016/j.ejps.2016.02.015

76. Jing-Jing LI, Guo MM, Han SP, et al. Preparation and in vitro evaluation of bongeol and folic acid co-modified doxorubicin loaded PAMAM drug delivery system. Acta Pharm Sin. 2015;50(7):899.

77. Khatoon M, Shah KU, Din FU, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 2017;24(sup1):56–69. doi:10.1080/10717544.2017.1384520

78. Bartelds R, Nematollahi MH, Pols T. Niosomes, an alternative for liposomal delivery. Pharmaceutics. 2016;8(1):224–235. doi:10.3390/pharmaceutics8010024

79. Lu F, Pang Z, Zhao J, et al. Angiopep-2-conjugated poly(ethylene glycol)-based amphiphile for combating glioblastoma. Mol Pharm. 2017;14:3592–3605. doi:10.1021/acs.jmedchem.6b01257

80. You T, Bi Y, Li J, et al. IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK/STAT signaling. Sci Rep. 2017;7:41197. doi:10.1038/s41598-017-04312-2

81. Bhunia S, Vangala V, Bhattacharya D, et al. Large amino acid transport 1 selective liposomes of 1-DOPA, functionalized amphiphile for combating glioblastoma. Mol Pharm. 2017;14(11):3834–3847. doi:10.1021/acs.molpharmaceut.7b00569

82. Malekloo N, Allameh A, Kazemi B. Preparation, characterization and in vitro-targeted delivery of novel Apolipoprotein E-based nanoparticles to C6 glioma with controlled size and loading efficiency. J Drug Target. 2016;24(4):348–358. doi:10.1080/10717544.2015.1077849

83. Lu F, Peng Z, Zhao J, et al. Angiopep-2-conjugated poly(ethylene glycol)-co-poly(e-caprolactone) polymersomes for dual-targeting drug delivery to glioma in rats. Int J Nanomedicine. 2017;12:2117–2127. doi:10.2147/IJN.S123422

84. Liang M, Gao C, Wang Y, et al. Enhanced blood–brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Drug Deliv. 2018;25(1):1652–1663. doi:10.1080/10717544.2018.1494223

85. Chai Z, Hu X, Wei X, et al. A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Controlled Release. 2017;264:102–111. doi:10.1016/j.jconrel.2017.08.027
96. Hu Q, Gu G, Liu Z, et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administered with tLyp-1 peptide for anti-glioma drug delivery. *Biomaterials*. 2013;34(4):1135–1145. doi:10.1016/j.biomaterials.2012.10.048

97. Liu Y, Mei L, Xu C, et al. Dual receptor recognizing cell penetrating peptide for selective targeting, efficient intratumoral diffusion and synthesized anti-glioma therapy. *Theranostics*. 2016;12(2):500.

98. Luo Z, Yan Z, Jin K, et al. Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-gamma-glutamylglutamine)-paclitaxel nanoconjugates. *J Colloid Interface Sci*. 2017;490:783–796. doi:10.1016/j.jcis.2016.12.004

99. Mu c, Nimita D, Jing H, et al. Solubilization of turbiproto into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro. *J Microencapsul*. 2013;30(7):701–708. doi:10.3109/02652048.2013.778907

100. Tinghui L, Susan M, Boris K, et al. A new interleukin-13 amino-coated gadolinium metallofullerene nanoparticle for targeted MRI detection of glioblastoma tumor cells. *J Am Chem Soc*. 2015;137(24):7881–7888. doi:10.1021/jacs.5b03991

101. Lee W, Nam JH, Cho HJ, et al. Epimedium koreanum Nakai inhibits PMA-induced cancer cell migration and invasion by modulating NF-κB/MMP-9 signaling in monomorphic malignant human glioma cells. *Oncol Rep*. 2017;38(6):3619–3631. doi:10.3892/or.2017.706043

102. Wang X, Gao J, Ouyang X, et al. Mesenchymal stem cells loaded with paclitaxel-poly(lactic-co-glycolic acid) nanoparticles for glioma-targeting therapy. *Int J Nanomedicine*. 2018;13:5231–5248. doi:10.2147/IJN.S167142

103. Liou L, Tao Y, Payne G, et al. Targeted delivery of nano-PTX to the brain tumor-associated macrophages. *Oncotarget*. 2016;8(4):6564–6578.

104. Peterson TE, Kirkpatrick ND, Huang Y, et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. *Proc Natl Acad Sci U S A*. 2016;113(16):4470–4475. doi:10.1073/pnas.1525349113

105. Zhang Y, Zhai M, Chen Z, et al. Dual-modified liposome delivery of doxorubicin and vincristine improve targeting and therapeutic efficiency. *Mater Sci Eng C*. 2016;67:159–169. doi:10.1016/j.msec.2016.05.012

106. Zou L, Tao Y, Payne G, et al. Targeted delivery of nano-PTX to the brain tumor-associated macrophages. *Oncotarget*. 2016;8(4):6564–6578.

107. Dela M, Motahal Ulrich H, et al. Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma. *J Neuro-Oncology*. 2015;87(9):806–816. doi:10.1002/cyto.a.22715

108. Yates-Reyes EM, Yun T, Bates PJ. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. *Cancer Res*. 2010;70(21):8617–8629. doi:10.1158/0008-5472.CAN-10-0920

109. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

110. Yin Y, Fu C, Li M, et al. A pH-sensitive hyaluronic acid prodruk modified with lactoferrin for glioma dual-targeted treatment. *Mater Sci Eng C*. 2016;67:159–169. doi:10.1016/j.msec.2016.05.012

111. Shibata S, Shinozaki N, Suganami A, et al. Doxorubicin-poly(l-lactic-co-glycolic acid) nanoparticles co-administrated with tLyp-1 peptide for glioma dual-targeted treatment. *Biomaterials*. 2013;34(4):1135–1145. doi:10.1016/j.biomaterials.2012.10.048

112. Yao Xue Xue Bao = Acta Pharmacuetica Sinica. 2015;50(1):99–103.

113. Dela M, Motahal Ulrich H, et al. Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma. *J Neuro-Oncology*. 2015;87(9):806–816. doi:10.1002/cyto.a.22715

114. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

115. Lu et al. 2017;13:5231–5248. doi:10.2147/IJN.S167142

116. Dela M, Motahal Ulrich H, et al. Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma. *J Neuro-Oncology*. 2015;87(9):806–816. doi:10.1002/cyto.a.22715

117. Dela M, Motahal Ulrich H, et al. Aptamer for imaging and therapeutic targeting of brain tumor glioblastoma. *J Neuro-Oncology*. 2015;87(9):806–816. doi:10.1002/cyto.a.22715

118. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

119. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

120. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

121. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

122. Bates PJ, Reyes-Reyes EM, Malik MT, et al. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: uses and mechanisms. *Biophys J Acta*. 2016;1861(5 Pt 1B):1414. doi:10.1016/j.bbadgen.2016.07.015

123. Joshi BH, Puri RA, Leland P, et al. Identification of interleukin-13 receptor a2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. *Neuro-Oncology*. 2008;10(3):265–274. doi:10.1215/15258577-2007-0066

124. Madhankumar AB, Slaglewebb B, Mintz A, et al. Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. *Mol Cancer Ther*. 2006;5(12):3162. doi:10.1158/1535-7163.MCT-06-0480

125. Madhankumar AB, Slagle-webb B, Wang X, et al. Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. *Mol Cancer Ther*. 2009;8(3):648–654. doi:10.1158/1535-7163.MCT-08-0853

126. Roger M, Clavreul A, Venier-Julienne MC, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. *Biomaterials*. 2010;31(32):3893–3901. doi:10.1016/j.biomaterials.2010.07.048

127. Zhang X, Yao S, Liu C, et al. Tumor tropic delivery of doxorubicin-polymer conjugates using mesenchymal stem cells for glioma therapy. *Biomaterials*. 2015;39:269–281. doi:10.1016/j.biomaterials.2014.11.003

128. Wang W, Liu F, Xiang B, et al. Stem cells as cellular vehicles for gene therapy against glioblastoma. *Int J Clin Exp Med*. 2015;8(10):17102.
129. Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6(4):268-286. doi:10.1016/j.apsb.2016.05.013

130. Felice B, Prabhakaran MP, Rodriguez AP, et al. Drug delivery vehicles on a nano-engineering perspective. Mater Sci Eng C. 2014;41:178-195. doi:10.1016/j.msec.2014.04.049

131. Bruschi ML, Borghi FB, Junqueira MV, et al. Environmentally responsive systems for drug delivery. Recent Pat Drug Deliv Formul. 2017;11(2):89–100. doi:10.2174/187211311666107328151455

132. Li SY, Cheng H, Xie BR, et al. Cancer cell membrane camouflaged cascade biocarrier for cancer targeted starvation and photodynamic therapy. ACS Nano. 2017;11(7):7006-7018. doi:10.1021/acsnano.7b02533

133. Pollack IF, Kawecki, S. The effect of calphostin C, a potent photodependent protein kinase C inhibitor, on the proliferation of glioma cells in vitro. J Neurooncol. 1997;31(3):255–266. doi:10.1023/A:1005729626354

134. Zhang J, Li J, Shi Z, et al. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities. Acta Biomater. 2017;58:349. doi:10.1016/j.actbio.2017.04.029

135. Zhang J, Chen R, Fang X, Chen F, Wang Y, Chen M. Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel. Nano Res. 2015;8(1):201–218. doi:10.1007/s12274-014-0619-4

136. Fang XB, Zhang JM, Xie X, et al. pH-sensitive micelles based on acid-labile pluronic F68-curcumin conjugates for improved tumor intracellular drug delivery. Int J Pharm. 2016;502(1-2):28–37. doi:10.1016/j.ijpharm.2016.01.029

137. Li M, Shi K, Tang X, et al. pH-sensitive folic acid and dNP2 peptide dual-modified liposome for enhanced targeted chemotherapy of glioma. Eur J Pharmacol. 2018;124:124240–124248. doi:10.1016/j.ejphar.2018.07.055

138. SS P, Mr R. Redox sensitive cationic pullulan for efficient gene transfection and drug retention in C6 glioma cells. Int J Pharm. 2017;530(1-2):401–414. doi:10.1016/j.ijpharm.2017.08.004

139. Yang X, Lv S, Liu Y, et al. The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):38–44. doi:10.1007/s12035-014-8850-2

140. Horne TK, Cronjé MJ. Mechanistics and photo-energetics of photodynamic therapy: an overview of aspects relevant to the cytosolic delivery of membranotropic peptide-functionalized platinum nanomolecules. Nanoscale. 2017;9(31):11288. doi:10.1039/C7NR02350B

141. Monteiro AF, Rato M, Martins C. Drug-induced photosensitivity: photoallergic and phototoxic reactions. Adv Drug Deliv Rev. 2018;132:16–32. doi:10.1016/j.addr.2018.05.007

142. Su Z, Xu Y, Wang Y, et al. A pH and reduction-sensitive polymeric nanomicelle for tumor microenvironment triggered cellular uptake and controlled intracellular drug release. Biomater Sci. 2019;7(9):3821–3831. doi:10.1039/C9BM00825J

143. Chen F, Zhang J, He Y, et al. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA. Biomater Sci. 2016;4(1):167–182. doi:10.1039/C5BM00224A

144. Chen F, Zhang J, Wang L, et al. Tumor pH- (e)-triggered charge-reversal and redox-responsive nanoparticles for docetaxel delivery in hepatocellular carcinoma treatment. Nanoscale. 2015;7(38):15763–15779. doi:10.1039/C5NR04612B

145. Chen FQ, Zhang JM, Fang XF, et al. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of alpha-tocopheryl succinate-based polyphosphoester polymers. Acta Pharmacol Sin. 2017;38(6):859–873. doi:10.1038/aps.2016.150

146. Kim MM, Lawrence TS, Yue C. Advances in magnetic resonance and positron emission tomography imaging: assessing response in the treatment of low-grade glioma. Semin Radiat Oncol. 2015;25(3):172–180. doi:10.1016/j.semradi onc.2015.02.003

147. Chen L, Cong D, Li Y, et al. Combination of sonodynamic with temozolomide inhibits C6 glioma migration and promotes mitochondrial pathway apoptosis via suppressing NHE-1 expression. Ultrason Sonochem. 2017;39:654. doi:10.1016/j.ultraschon.2017.05.013

148. Guarnieri D, Melone P, Moglianietti M, et al. Particle size affects the cytotoxic delivery of membranotropic peptide-functionalized platinum nanomolecules. Nanoscale. 2017;9(31):11288. doi:10.1039/C7NR02350B

149. Wang T, Wang L, Li X, et al. Size-dependent regulation of intracellular trafficking of polysytrene nanoparticle-based drug delivery carriers. ACS Appl Mater Interfaces. 2017;9(22):18619. doi:10.1021/acsami.7b05383

150. Fan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm. 2008;359(1-2):104–110. doi:10.1016/j.ijpharm.2008.03.030

151. Bi C, Miao QX, Chow SF, et al. Particle size effect of curcumin nanoparticles on cytotoxicity, cellular internalization, in vivo pharmacokinetics and biodistribution. Nanomed Nanotechnol Biol Med. 2016;13(3):943–953. doi:10.1016/j.nano.2016.11.004

152. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35–58. doi:10.2165/0023210-20092301-00003

153. Zhang F, Xu CL, Liu CM. Drug delivery strategies to enhance the efficacy of tanshinone IIA. Acta Pharmacol Sin. 2013;34(5):571–581. doi:10.1038/aps.2013.50

154. Jia Y, Wang X, Hu D, et al. Phototheranostics: active targeting of orthotopic glioma using bioimprinted protein nanoparticles. ACS Nano. 2019;13(1):386–398. doi:10.1021/acsnano.8b06556

155. Johung T, Monje M. Neuronal activity in the glioma microenvironment. Curr Opin Neurobiol. 2017;47:156–161. doi:10.1016/j.conb.2017.10.009

156. Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2016;387:61–68. doi:10.1016/j.canlet.2016.01.043

157. Zheng XC, Ren W, Zhang S, et al. The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2018;13:1495–1504. doi:10.2147/IJN.S157082

158. Zhao Y, Ren W, Zhong T, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Controlled Release. 2016;222:56–66. doi:10.1016/j.jconrel.2015.12.006

159. Stephen ZR, Gebhart RN, Jeon M, et al. pH-sensitive O6-benzyguanosine polymer modified magnetic nanoparticles for treatment of glioblastomas. Bioconjug Chem. 2016;28(1):194–202. doi:10.1021/acs.bioconjugchem.6b00545

160. He-Lin X, Zi-Liang F, De-Li Z, et al. Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive core–shell nanoparticles targeting the heterogeneous tumor cells of glioma. Drug Deliv. 2018;25(1):1302–1318. doi:10.1080/10717544.2018.1474974

161. Sun H, Zhang Y, Zhong Z. Reduction-sensitive polymeric nanomedicines: an emerging multifunctional platform for targeted cancer therapy. Adv Drug Deliv Rev. 2018;132:16–32. doi:10.1016/j.addr.2018.05.007

162. Li et al. International Journal of Nanomedicine 2020:15
Li et al

163. Hong-jin W, Jun-jie W, Qiang X, et al. Effect factors and mechanisms of borneol’s bidirectional regulation on blood-brain barrier permeability. China J Chin Mater Med. 2017;42(11):2200–2207. doi:10.19540/j.cnki.cjcm.2017.0100

164. Li-ping W, Jian-fang F, Kai-li H. Progress in regulation effect of aromatic refreshing traditional Chinese medicine on BBB permeability and its mechanism. China J Chin Mater Med. 2014;39(6):949–954.

165. Zheng Q, Chen ZX, Xu MB, et al. Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood–brain barrier permeability: a preclinical systematic review and meta-analysis. Drug Deliv. 2018;25(1):1617–1633. doi:10.1080/10717544.2018.1486471

166. Zhang QL, Fu BM, Zhang ZJ. Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability. Drug Deliv. 2017;24(1):1037. doi:10.1080/10717544.2017.1346002

167. Yuan X, Fei F, Sun H, et al. Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo. Int J Nanomedicine. 2018;13:2265–2274. doi:10.2147/IJN.S159789

168. Lin Z, Limei H, Jing Q, et al. The use of borneol as an enhancer for targeting aprotinin-conjugated PEG-PLGA nanoparticles to the brain. Pharm Res. 2013;30(10):2560–2572. doi:10.1007/s11095-013-1055-y

169. Yin Y, Cao L, Ge H, et al. L-Borneol induces transient opening of the blood–brain barrier and enhances the therapeutic effect of cisplatin. Neuroreport. 2017;28(9):506. doi:10.1097/WNR.0000000000007972

170. Wu JY, Li YJ, Yang L, et al. Borneol and A-asarone as adjuvant agents for improving blood–brain barrier permeability of puerarin and tetramethylpyrazine by activating adenosine receptors. Drug Deliv. 2018;25(1):1858–1864. doi:10.1080/10717544.2018.1516005

171. Dgr E, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(12):e54. doi:10.1186/1078-0432.CCR-17-0590

172. Yoon YI, Yoon TJ, Lee HJ. Optimization of ultrasound parameters for microbubble-nanoposome complex-mediated delivery. Ultrasonography. 2015;34(4):297–303. doi:10.14366/usg.15009

173. Chen L, Cui-Tao LU, Zhao YZ, et al. Ultrasound microbubbles for glioma-targeted drug delivery. Yao Xue Xue Bao = Acta Pharmacueutica Sinica. 2015;50(1):99–103.

174. Sennoga CA, Kanbar E, Auboire L, et al. Microbubble-mediated ultrasound drug-delivery and therapeutic monitoring. Expert Opin Drug Deliv. 2017;14(9):1031–1043. doi:10.1080/17425247.2017.1266328

175. Marcel Menon M, Bleier BS. The blood-brain barrier and nasal drug delivery to the central nervous system. Am J Rhinol Allergy. 2015;29(2):124–127. doi:10.2500/ajra.2015.29.4149

176. Zhang LK, Ri-Xin XU, Jiang M, et al. Evaluation of brain-targeting of β-asarone microemulsion by intranasal administration. Chin Traditional Herbal Drugs. 2014;45(1):86–89.

177. Nair A. Implications of intrathecal chemotherapy for anaesthesiologists: a brief review. Scientifica,2016,(2016-3-31).2016;2016(5):1–5.

178. Kumari S, Ahsan SM, Kumar JM, et al. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep. 2017;7(1):6602. doi:10.1038/s41598-017-06888-4